Income Statement
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
KNSA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Revenue
|
677.56 | 423.24 | 270.26 | 220.18 | 38.54 | - | - | - |
|
Cost of Revenue
|
77.67 | 60.91 | 56.52 | 24.07 | 9.10 | - | - | - |
|
Gross Profit
|
599.89 | 362.33 | 213.74 | 196.11 | 29.44 | - | - | - |
|
Operating Expenses
|
293.13 | 279.63 | 205.52 | 163.44 | 185.25 | 157.36 | 169.96 | 108.16 |
|
Research & Development
|
96.85 | 111.62 | 76.10 | 65.49 | 99.30 | 112.04 | 135.00 | 86.60 |
|
Selling, General & Administrative
|
196.27 | 168.01 | 129.43 | 97.95 | 85.95 | 45.32 | 34.96 | 21.56 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - |
|
Operating Income
|
306.77 | 82.70 | 8.21 | 32.67 | -155.80 | -157.36 | -169.96 | -108.16 |
|
Non-Operating Income
|
217.90 | 118.85 | 24.86 | 21.64 | 0.74 | -1.13 | -6.05 | -4.72 |
|
Interest Income
|
11.64 | 9.04 | - | - | 0.10 | 1.13 | 6.05 | 4.72 |
|
Interest Expense
|
- | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | - | - |
|
Income Before Tax
|
88.87 | -36.15 | -16.65 | 11.03 | -156.54 | -156.23 | -163.91 | -103.44 |
|
Income Tax Expense
|
29.86 | 7.04 | -30.74 | -172.34 | 1.39 | 5.15 | -2.05 | -0.21 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - |
|
Net Income
|
59.01 | -43.19 | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 | -103.23 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - |
|
EBITDA
|
308.32 | 84.39 | 10.55 | 35.07 | -153.45 | -157.36 | -169.96 | -108.16 |
|
Earnings Per Share (Basic)
|
0.80 | -0.60 | 0.20 | 2.64 | -2.30 | - | - | - |
|
Diluted EPS
|
0.75 | -0.60 | 0.20 | 2.60 | -2.30 | - | - | - |
|
Weighted Average Shares
|
74.20 | 71.42 | 70.06 | 69.38 | 68.58 | - | - | - |
|
Diluted Weighted Avg Shares
|
78.98 | 71.42 | 71.92 | 70.42 | 68.58 | - | - | - |
|
Comprehensive Income
|
59.14 | -43.36 | 14.05 | 183.47 | -157.96 | -161.45 | -161.83 | -103.23 |